Imdelltra™ (tarlatamab-dlle) – New drug approval
May 16, 2024 - Amgen announced the FDA approval of Imdelltra (tarlatamab-dlle), for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.